Association of coronary artery calcification with liver fibrosis in Japanese patients with non-alcoholic fatty liver disease

Aims Cardiovascular events are the leading cause of death among patients with non‐alcoholic fatty liver disease (NAFLD), but their relationship remains unclear. This study examined the association between coronary atherosclerosis and liver fibrosis, represented by the coronary artery calcification (...

Full description

Saved in:
Bibliographic Details
Published inHepatology research Vol. 46; no. 11; pp. 1107 - 1117
Main Authors Ishiba, Hiroshi, Sumida, Yoshio, Kataoka, Seita, Kuroda, Masaaki, Akabame, Satoshi, Tomiyasu, Kiichiro, Tanaka, Muhei, Arai, Masahiro, Taketani, Hiroyoshi, Seko, Yuya, Okajima, Akira, Hara, Tasuku, Umemura, Atsushi, Nishikawa, Taichiro, Yamaguchi, Kanji, Moriguchi, Michihisa, Mitsuyoshi, Hironori, Yasui, Kohichiroh, Itoh, Yoshito
Format Journal Article
LanguageEnglish
Published Netherlands Blackwell Publishing Ltd 01.10.2016
Subjects
Online AccessGet full text
ISSN1386-6346
1872-034X
DOI10.1111/hepr.12665

Cover

Abstract Aims Cardiovascular events are the leading cause of death among patients with non‐alcoholic fatty liver disease (NAFLD), but their relationship remains unclear. This study examined the association between coronary atherosclerosis and liver fibrosis, represented by the coronary artery calcification (CAC) score and non‐invasive fibrosis markers, respectively. Methods Among 698 patients with chest pain or electrocardiographic abnormalities who underwent coronary computed tomography (CT) between April 2006 and March 2010, those with known liver disorders or history of emergency coronary angioplasty were excluded, leaving 366 patients for this study. Diagnosis of NAFLD was based on abdominal CT and history of alcohol consumption. Subjects with CAC of 100 AU or more were categorized into the high‐risk group for cardiovascular events. Patient records were examined for clinical parameters including CAC score and non‐invasive fibrosis marker FIB‐4 index. Results Ninety‐four patients (25.7%) had NAFLD. In this group, univariate analysis identified old age, high diastolic blood pressure, high liver to spleen ratio and high FIB‐4 index as risk factors for cardiovascular events and multivariate analysis identified age of 66 years or older and FIB‐4 index of 2.09 or more as the significant risk factors. For the observation period until August 2014, the cumulative proportion of PCI performance was significantly higher in patients with FIB‐4 of 2.09 or more than those with FIB‐4 of less than 2.09. Conclusion The progression of arteriosclerosis and that of liver fibrosis may be associated in NAFLD patients. The FIB‐4 index can be easily determined and thus can be a useful marker for predicting cardiovascular events in NAFLD patients.
AbstractList Aims Cardiovascular events are the leading cause of death among patients with non‐alcoholic fatty liver disease (NAFLD), but their relationship remains unclear. This study examined the association between coronary atherosclerosis and liver fibrosis, represented by the coronary artery calcification (CAC) score and non‐invasive fibrosis markers, respectively. Methods Among 698 patients with chest pain or electrocardiographic abnormalities who underwent coronary computed tomography (CT) between April 2006 and March 2010, those with known liver disorders or history of emergency coronary angioplasty were excluded, leaving 366 patients for this study. Diagnosis of NAFLD was based on abdominal CT and history of alcohol consumption. Subjects with CAC of 100 AU or more were categorized into the high‐risk group for cardiovascular events. Patient records were examined for clinical parameters including CAC score and non‐invasive fibrosis marker FIB‐4 index. Results Ninety‐four patients (25.7%) had NAFLD. In this group, univariate analysis identified old age, high diastolic blood pressure, high liver to spleen ratio and high FIB‐4 index as risk factors for cardiovascular events and multivariate analysis identified age of 66 years or older and FIB‐4 index of 2.09 or more as the significant risk factors. For the observation period until August 2014, the cumulative proportion of PCI performance was significantly higher in patients with FIB‐4 of 2.09 or more than those with FIB‐4 of less than 2.09. Conclusion The progression of arteriosclerosis and that of liver fibrosis may be associated in NAFLD patients. The FIB‐4 index can be easily determined and thus can be a useful marker for predicting cardiovascular events in NAFLD patients.
AIMSCardiovascular events are the leading cause of death among patients with non-alcoholic fatty liver disease (NAFLD), but their relationship remains unclear. This study examined the association between coronary atherosclerosis and liver fibrosis, represented by the coronary artery calcification (CAC) score and non-invasive fibrosis markers, respectively.METHODSAmong 698 patients with chest pain or electrocardiographic abnormalities who underwent coronary computed tomography (CT) between April 2006 and March 2010, those with known liver disorders or history of emergency coronary angioplasty were excluded, leaving 366 patients for this study. Diagnosis of NAFLD was based on abdominal CT and history of alcohol consumption. Subjects with CAC of 100 AU or more were categorized into the high-risk group for cardiovascular events. Patient records were examined for clinical parameters including CAC score and non-invasive fibrosis marker FIB-4 index.RESULTSNinety-four patients (25.7%) had NAFLD. In this group, univariate analysis identified old age, high diastolic blood pressure, high liver to spleen ratio and high FIB-4 index as risk factors for cardiovascular events and multivariate analysis identified age of 66 years or older and FIB-4 index of 2.09 or more as the significant risk factors. For the observation period until August 2014, the cumulative proportion of PCI performance was significantly higher in patients with FIB-4 of 2.09 or more than those with FIB-4 of less than 2.09.CONCLUSIONThe progression of arteriosclerosis and that of liver fibrosis may be associated in NAFLD patients. The FIB-4 index can be easily determined and thus can be a useful marker for predicting cardiovascular events in NAFLD patients.
Cardiovascular events are the leading cause of death among patients with non-alcoholic fatty liver disease (NAFLD), but their relationship remains unclear. This study examined the association between coronary atherosclerosis and liver fibrosis, represented by the coronary artery calcification (CAC) score and non-invasive fibrosis markers, respectively. Among 698 patients with chest pain or electrocardiographic abnormalities who underwent coronary computed tomography (CT) between April 2006 and March 2010, those with known liver disorders or history of emergency coronary angioplasty were excluded, leaving 366 patients for this study. Diagnosis of NAFLD was based on abdominal CT and history of alcohol consumption. Subjects with CAC of 100 AU or more were categorized into the high-risk group for cardiovascular events. Patient records were examined for clinical parameters including CAC score and non-invasive fibrosis marker FIB-4 index. Ninety-four patients (25.7%) had NAFLD. In this group, univariate analysis identified old age, high diastolic blood pressure, high liver to spleen ratio and high FIB-4 index as risk factors for cardiovascular events and multivariate analysis identified age of 66 years or older and FIB-4 index of 2.09 or more as the significant risk factors. For the observation period until August 2014, the cumulative proportion of PCI performance was significantly higher in patients with FIB-4 of 2.09 or more than those with FIB-4 of less than 2.09. The progression of arteriosclerosis and that of liver fibrosis may be associated in NAFLD patients. The FIB-4 index can be easily determined and thus can be a useful marker for predicting cardiovascular events in NAFLD patients.
Author Arai, Masahiro
Taketani, Hiroyoshi
Ishiba, Hiroshi
Sumida, Yoshio
Tanaka, Muhei
Hara, Tasuku
Akabame, Satoshi
Seko, Yuya
Moriguchi, Michihisa
Yasui, Kohichiroh
Yamaguchi, Kanji
Mitsuyoshi, Hironori
Nishikawa, Taichiro
Kataoka, Seita
Kuroda, Masaaki
Tomiyasu, Kiichiro
Umemura, Atsushi
Okajima, Akira
Itoh, Yoshito
Author_xml – sequence: 1
  givenname: Hiroshi
  surname: Ishiba
  fullname: Ishiba, Hiroshi
  organization: Departments of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine
– sequence: 2
  givenname: Yoshio
  surname: Sumida
  fullname: Sumida, Yoshio
  email: sumida@koto.kpu-m.ac.jp, sumida@koto.kpu-m.ac.jp
  organization: Departments of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine
– sequence: 3
  givenname: Seita
  surname: Kataoka
  fullname: Kataoka, Seita
  organization: Department of Gastroenterology, Kyoto Yamashiro General Medical Center
– sequence: 4
  givenname: Masaaki
  surname: Kuroda
  fullname: Kuroda, Masaaki
  organization: Department of Gastroenterology, Kyoto Yamashiro General Medical Center
– sequence: 5
  givenname: Satoshi
  surname: Akabame
  fullname: Akabame, Satoshi
  organization: Department of Cardiology, Kyoto Yamashiro General Medical Center
– sequence: 6
  givenname: Kiichiro
  surname: Tomiyasu
  fullname: Tomiyasu, Kiichiro
  organization: Department of Cardiology, Kyoto Yamashiro General Medical Center
– sequence: 7
  givenname: Muhei
  surname: Tanaka
  fullname: Tanaka, Muhei
  organization: Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Kyoto, Japan
– sequence: 8
  givenname: Masahiro
  surname: Arai
  fullname: Arai, Masahiro
  organization: Department of Gastroenterology, Kyoto Yamashiro General Medical Center
– sequence: 9
  givenname: Hiroyoshi
  surname: Taketani
  fullname: Taketani, Hiroyoshi
  organization: Departments of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine
– sequence: 10
  givenname: Yuya
  surname: Seko
  fullname: Seko, Yuya
  organization: Departments of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine
– sequence: 11
  givenname: Akira
  surname: Okajima
  fullname: Okajima, Akira
  organization: Departments of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine
– sequence: 12
  givenname: Tasuku
  surname: Hara
  fullname: Hara, Tasuku
  organization: Departments of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine
– sequence: 13
  givenname: Atsushi
  surname: Umemura
  fullname: Umemura, Atsushi
  organization: Departments of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine
– sequence: 14
  givenname: Taichiro
  surname: Nishikawa
  fullname: Nishikawa, Taichiro
  organization: Departments of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine
– sequence: 15
  givenname: Kanji
  surname: Yamaguchi
  fullname: Yamaguchi, Kanji
  organization: Departments of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine
– sequence: 16
  givenname: Michihisa
  surname: Moriguchi
  fullname: Moriguchi, Michihisa
  organization: Departments of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine
– sequence: 17
  givenname: Hironori
  surname: Mitsuyoshi
  fullname: Mitsuyoshi, Hironori
  organization: Departments of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine
– sequence: 18
  givenname: Kohichiroh
  surname: Yasui
  fullname: Yasui, Kohichiroh
  organization: Departments of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine
– sequence: 19
  givenname: Yoshito
  surname: Itoh
  fullname: Itoh, Yoshito
  organization: Departments of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26853695$$D View this record in MEDLINE/PubMed
BookMark eNp9kdtLHDEUh4Mo3tqX_gElj6UwmstMknkUsV7whrasbyETz7BpZydjkq1d8I8366w-SDEEkofvO5zzOztovfc9IPSFkj2az_4UhrBHmRDVGtqmSrKC8PJuPf-5EoXgpdhCOzH-JoRKwspNtMWEqrioq230dBCjt84k53vsW2x98L0JC2xCgvxY01nXOjsCjy5Ncef-QsCta4KPLmLX4zMzmB4i4CFj0Kc4grnNIut-6jtncWtSWqzkexfBRPiENlrTRfi8enfRrx9HPw9PivOr49PDg_PCloJWRdnUHJQkhgOUhJYqX8ulaSoj2zxIY1XdQFUxCZxQxrht88yNrAXljCvGd9G3se4Q_MMcYtIzFy10Xe7az6OmahkeqwXJ6NcVOm9mcK-H4GY5Dv2aWAa-j4DN48cA7RtCiV6uQy_XoV_WkWHyDrYuvUSZgnHd_xU6Ko-ug8UHxfXJ0fXNq1OMjosJ_r05JvzRQnJZ6cnlsZ6oi9t6cn2nb_kzhLCtsQ
CitedBy_id crossref_primary_10_12998_wjcc_v8_i20_4688
crossref_primary_10_3390_biomedicines10071496
crossref_primary_10_1016_j_jacc_2018_11_050
crossref_primary_10_1016_j_numecd_2024_10_006
crossref_primary_10_1016_j_cgh_2020_07_030
crossref_primary_10_1007_s10554_023_02858_2
crossref_primary_10_1093_ehjopen_oeac030
crossref_primary_10_3390_ijms251910595
crossref_primary_10_1038_s41598_020_75266_4
crossref_primary_10_1111_hepr_13706
crossref_primary_10_31083_j_rcm2509344
crossref_primary_10_1111_hepr_13190
crossref_primary_10_3390_jcm10081569
crossref_primary_10_1007_s10620_024_08450_5
crossref_primary_10_3390_ijms18091941
crossref_primary_10_3390_life11020143
crossref_primary_10_1186_s12959_022_00441_8
crossref_primary_10_3390_biomedicines10081770
crossref_primary_10_1177_2050312120933804
crossref_primary_10_18087_cardio_2023_7_n2258
Cites_doi 10.1016/S0016-5085(99)70506-8
10.1002/hep.26156
10.1111/j.1478-3231.2008.01691.x
10.1586/17474124.2015.965143
10.1136/gut.2007.146019
10.1053/j.gastro.2005.11.017
10.1161/CIRCULATIONAHA.106.178458
10.1001/jama.2012.9624
10.1002/hep.25593
10.1097/MEG.0000000000000286
10.3748/wjg.v19.i8.1219
10.1002/hep.21178
10.1053/jhep.2003.50346
10.1100/2012/931386
10.1210/er.2008-0009
10.1111/eci.12092
10.1002/hep.27368
10.2337/dc12-0515
10.1053/j.gastro.2007.03.059
10.1002/hep.20466
10.1016/j.tem.2008.08.005
10.1111/hepr.12405
10.1007/s12350-009-9159-9
10.1007/BF00280883
10.1111/j.1572-0241.1999.01377.x
10.1111/jgh.12992
10.1186/1471-230X-12-2
10.1053/j.gastro.2007.03.058
10.1016/0021-9681(87)90129-9
10.1016/j.jacc.2006.10.079
10.1002/hep.20734
10.1111/j.1478-3231.2007.01545.x
10.1016/j.jacc.2012.12.035
10.1016/j.mayocp.2013.06.025
10.1097/01.TP.0000140499.23683.0D
10.1016/0735-1097(90)90282-T
10.1016/j.metabol.2013.01.018
10.1056/NEJMra0912063
10.1016/j.atherosclerosis.2006.08.021
10.1007/s10557-011-6341-5
10.1016/j.cgh.2009.05.033
10.2337/dc07-0349
10.4065/74.3.243
10.1373/clinchem.2009.140707
10.1016/j.cgh.2008.11.005
10.3748/wjg.v20.i2.475
ContentType Journal Article
Copyright 2016 The Japan Society of Hepatology
2016 The Japan Society of Hepatology.
Copyright_xml – notice: 2016 The Japan Society of Hepatology
– notice: 2016 The Japan Society of Hepatology.
DBID BSCLL
AAYXX
CITATION
NPM
7X8
DOI 10.1111/hepr.12665
DatabaseName Istex
CrossRef
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1872-034X
EndPage 1117
ExternalDocumentID 26853695
10_1111_hepr_12665
HEPR12665
ark_67375_WNG_W8MS9WPX_S
Genre article
Journal Article
GroupedDBID ---
--K
.3N
.GA
.Y3
05W
0R~
10A
1B1
1OC
1~5
29I
31~
33P
3SF
4.4
4G.
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
7-5
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAEDT
AAESR
AAEVG
AAHQN
AAIPD
AALRI
AAMMB
AAMNL
AANHP
AANLZ
AAONW
AAQFI
AAQXK
AASGY
AAXRX
AAXUO
AAYCA
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABIJN
ABJNI
ABPVW
ABQWH
ABWVN
ABXGK
ACAHQ
ACBWZ
ACCZN
ACGFO
ACGFS
ACGOF
ACIUM
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACUHS
ACVFH
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADCNI
ADEOM
ADIZJ
ADKYN
ADMGS
ADMUD
ADNMO
ADOZA
ADXAS
ADZMN
AEFGJ
AEGXH
AEIGN
AEIMD
AENEX
AEUPX
AEUYR
AEYWJ
AFBPY
AFFPM
AFGKR
AFPUW
AFWVQ
AFZJQ
AGHNM
AGQPQ
AGXDD
AGYGG
AHBTC
AIACR
AIAGR
AIDQK
AIDYY
AIGII
AITUG
AITYG
AIURR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBD
EBS
EJD
ESX
EX3
F00
F01
F04
F5P
FDB
FEDTE
FGOYB
FUBAC
G-Q
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M41
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NQ-
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
Q.N
Q11
QB0
R.K
R2-
ROL
RPZ
RX1
SEW
SSZ
SUPJJ
TEORI
TUS
UB1
UHS
V8K
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WVDHM
WXI
WXSBR
XG1
ZZTAW
~IA
~WT
AAYXX
CITATION
AAHHS
ACCFJ
ADZOD
AEEZP
AEQDE
AIWBW
AJBDE
NPM
RIG
7X8
ID FETCH-LOGICAL-c4615-4b93e870a3ee40148148c37ab5a7f853bc89be5527e301223cf346b7961323823
IEDL.DBID DR2
ISSN 1386-6346
IngestDate Thu Jul 10 18:09:34 EDT 2025
Thu Apr 03 07:02:36 EDT 2025
Thu Apr 24 23:06:04 EDT 2025
Wed Oct 01 02:40:25 EDT 2025
Wed Aug 20 07:25:24 EDT 2025
Sun Sep 21 06:17:21 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords coronary artery disease
liver fibrosis
non-alcoholic fatty liver disease
coronary artery calcification
FIB-4 index
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
2016 The Japan Society of Hepatology.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4615-4b93e870a3ee40148148c37ab5a7f853bc89be5527e301223cf346b7961323823
Notes istex:CDC71E86F805ECCB785A3606AC111118B3A789E5
ArticleID:HEPR12665
ark:/67375/WNG-W8MS9WPX-S
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 26853695
PQID 1826652960
PQPubID 23479
PageCount 11
ParticipantIDs proquest_miscellaneous_1826652960
pubmed_primary_26853695
crossref_primary_10_1111_hepr_12665
crossref_citationtrail_10_1111_hepr_12665
wiley_primary_10_1111_hepr_12665_HEPR12665
istex_primary_ark_67375_WNG_W8MS9WPX_S
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate October 2016
PublicationDateYYYYMMDD 2016-10-01
PublicationDate_xml – month: 10
  year: 2016
  text: October 2016
PublicationDecade 2010
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Hepatology research
PublicationTitleAlternate Hepatol Res
PublicationYear 2016
Publisher Blackwell Publishing Ltd
Publisher_xml – name: Blackwell Publishing Ltd
References Budoff MJ, Shaw LJ, Liu ST, et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol 2007; 49: 1860-70.
Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ; Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1104-1112.
Kim D, Choi SY, Park EH, et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology 2012; 56: 605-13.
Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57: 1441-7.
Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-50.
Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007; 191: 235-40.
Budoff MJ, Young R, Lopez VA, et al. Progression of coronary calcium and incident coronary heart disease events: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2013; 61: 1231-9.
Ishiba H, Sumida Y, Tanaka S et al. Plasma soluble lectin-like oxidized LDL receptor 1, a novel marker for atherosclerosis, is clinically associated with NAFLD histological severity. Hepatogastroenterology in press.
Mitra S, Goyal T, Metha JL. Oxidized LDL, LOX-1 and atherosclerosis. Cardiovasc Drugs Ther 2011; 25: 419-29.
Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15: 827-32.
Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2014; 20: 475-85.
Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61: 1547-54.
Takahashi Y, Kurosaki M, Tamaki N, et al. Non-alcoholic fatty liver disease fibrosis score and FIB-4 scoring system could identify patients at risk of systemic complications. Hepatology Research 2015; 45: 667-75.
Fukui M, Tanaka M, Senmaru T, et al. LOX-1 is a novel marker for peripheral artery disease in patients with type 2 diabetes. Metabolism 2013; 62: 935-8.
Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
Japan Atherosclerosis Society (JAS). Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012. Tokyo: JAS, 2012.
Myers RP, Fong A, Shaheen AA. Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies. Liver Int 2008; 28: 705-12.
Taye A, El-Sheikh AA. Lectin-like oxidized low-density lipoprotein receptor 1 pathways. Eur J Clin Invest 2013; 43: 740-5.
Dogan S, Celikbilek M, Yilmaz YK, et al. Association between liver fibrosis and coronary heart disease risk in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2015; 27: 298-304.
Bybee KA, Lee J, Markiewicz R, et al. Diagnostic and clinical benefit of combined coronary calcium and perfusion assessment in patients undergoing PET/CT myocardial perfusion stress imaging. J Nucl Cardiol 2010; 17: 188-96.
Inoue N, Okamura T, Kokubo Y, et al. LOX index, a novel predictive biochemical marker for coronary heart disease and stroke. Clin Chem 2010; 56: 550-8.
Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-25.
Day CP. From fat to inflammation. Gastroenterology 2006; 130: 207-10.
Budoff MJ, Achenbach S, Blumenthal RS, et al. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation 2006; 114: 1761-91.
Leaverton PE, Sorlie PD, Kleinman JC, et al. Representativeness of the Framingham risk model for coronary heart disease mortality: a comparison with a national cohort study. J Chronic Dis 1987; 40: 775-84.
Chhabra R, O'Keefe JH, Patil H et al. Association of coronary artery calcification with hepatic steatosis in asymptomatic individuals. Mayo Clin Proc 2013; 88: 1259-1265.
Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-95.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Home- ostasis model assessment: insulin resistance and -cell function from fasting glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
Iwasaki M, Takada Y, Hayashi M, et al. Noninvasive evaluation of graft steatosis in living donor liver transplantation. Transplantation 2004; 78: 1501-5.
Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52.
Treeprasertsuk S, Björnsson E, Enders F, Suwanwalaikorn S, Lindor KD. NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol 2013; 19: 1219-29.
Stefan N, Kantartzis K, Häring HU. Causes and metabolic consequences of fatty liver. Endocr Rev 2008; 29: 939-60.
Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7: 234-8.
Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 2012; 308: 788-95.
Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
Sumida Y, Yoneda M, Hyogo H, et al. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol 2012; 12: 2.
Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013; 57: 1357-65.
You SC, Kim KJ, Kim SU, et al. Hepatic fibrosis assessed using transient elastography is independently associated with coronary artery calcification. J Gastroenterol Hepatol 2015; 30: 1536-42.
Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007; 132: 2169-80.
Sattler S, Ghadially H, Hofer E. Evolution of the C-type lectin-like receptor genes of the DECTIN-1 cluster in the NK gene complex. Scientific World Journal 2012; 2012: 931386.
Adibi P, Sadeghi M, Mahsa M, Rozati G, Mohseni M. Prediction of coronary atherosclerotic disease with liver transaminase level. Liver Int 2007; 27: 895-900.
Badman MK, Flier JS. The adipocyte as an active participant in energy balance and metabolism. Gastroenterology 2007; 132: 2103-15.
Rumberger JA, Brundage BH, Rader DJ, Kondos G. Electron beam computed tomographic coronary calcium scanning: a review and guidelines for use in asymptomatic persons. Mayo Clin Proc 1999; 74: 243-52.
Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007; 30: 2119-21.
Sung KC, Wild SH, Kwag HJ, Byrne CD. Fatty liver, insulin resistance, and features of metabolic syndrome: relationships with coronary artery calcium in 10,153 people. Diabetes Care 2012; 35: 2359-64.
Tilg H, Moschen AR. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab 2008; 19: 371-9.
Lonardo A, Ballestri S, Targher G, Loria P. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2015; 9: 629-50.
2010; 56
1985; 28
2004; 40
2012; 2012
2012
1990; 15
2013; 88
2013; 43
2010; 17
2013; 62
2013; 61
2015; 30
2008; 19
2010; 363
2006; 130
2005; 42
2003; 38
2008; 57
2007; 191
2007; 30
2012; 35
2015; 9
2012; 56
2012; 12
2006; 114
2012; 308
2014; 20
2013; 19
2015; 45
2015; 27
1987; 40
2013; 57
2006; 43
2015; 61
2007; 132
2008; 29
2004; 78
2008; 28
2009; 7
1999; 74
2011; 25
1999; 94
1999; 116
2007; 27
2007; 49
e_1_2_6_32_1
e_1_2_6_30_1
e_1_2_6_19_1
e_1_2_6_13_1
e_1_2_6_36_1
e_1_2_6_11_1
e_1_2_6_34_1
e_1_2_6_17_1
e_1_2_6_15_1
e_1_2_6_38_1
e_1_2_6_43_1
e_1_2_6_20_1
e_1_2_6_41_1
Japan Atherosclerosis Society (JAS) (e_1_2_6_21_1) 2012
e_1_2_6_9_1
e_1_2_6_5_1
Ishiba H (e_1_2_6_46_1)
e_1_2_6_7_1
e_1_2_6_24_1
e_1_2_6_49_1
e_1_2_6_3_1
e_1_2_6_22_1
e_1_2_6_28_1
e_1_2_6_45_1
e_1_2_6_26_1
e_1_2_6_47_1
e_1_2_6_10_1
e_1_2_6_31_1
e_1_2_6_50_1
e_1_2_6_14_1
e_1_2_6_35_1
e_1_2_6_12_1
e_1_2_6_33_1
e_1_2_6_18_1
e_1_2_6_39_1
e_1_2_6_16_1
e_1_2_6_37_1
e_1_2_6_42_1
e_1_2_6_40_1
e_1_2_6_8_1
e_1_2_6_4_1
e_1_2_6_6_1
e_1_2_6_25_1
e_1_2_6_48_1
e_1_2_6_23_1
e_1_2_6_2_1
e_1_2_6_29_1
e_1_2_6_44_1
e_1_2_6_27_1
References_xml – reference: Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7: 234-8.
– reference: Bybee KA, Lee J, Markiewicz R, et al. Diagnostic and clinical benefit of combined coronary calcium and perfusion assessment in patients undergoing PET/CT myocardial perfusion stress imaging. J Nucl Cardiol 2010; 17: 188-96.
– reference: Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 2012; 308: 788-95.
– reference: Budoff MJ, Young R, Lopez VA, et al. Progression of coronary calcium and incident coronary heart disease events: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2013; 61: 1231-9.
– reference: Mitra S, Goyal T, Metha JL. Oxidized LDL, LOX-1 and atherosclerosis. Cardiovasc Drugs Ther 2011; 25: 419-29.
– reference: Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2014; 20: 475-85.
– reference: Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Home- ostasis model assessment: insulin resistance and -cell function from fasting glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
– reference: Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57: 1441-7.
– reference: Iwasaki M, Takada Y, Hayashi M, et al. Noninvasive evaluation of graft steatosis in living donor liver transplantation. Transplantation 2004; 78: 1501-5.
– reference: Day CP. From fat to inflammation. Gastroenterology 2006; 130: 207-10.
– reference: Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-95.
– reference: Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007; 30: 2119-21.
– reference: Budoff MJ, Shaw LJ, Liu ST, et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol 2007; 49: 1860-70.
– reference: Ishiba H, Sumida Y, Tanaka S et al. Plasma soluble lectin-like oxidized LDL receptor 1, a novel marker for atherosclerosis, is clinically associated with NAFLD histological severity. Hepatogastroenterology in press.
– reference: Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ; Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1104-1112.
– reference: Leaverton PE, Sorlie PD, Kleinman JC, et al. Representativeness of the Framingham risk model for coronary heart disease mortality: a comparison with a national cohort study. J Chronic Dis 1987; 40: 775-84.
– reference: Stefan N, Kantartzis K, Häring HU. Causes and metabolic consequences of fatty liver. Endocr Rev 2008; 29: 939-60.
– reference: Budoff MJ, Achenbach S, Blumenthal RS, et al. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation 2006; 114: 1761-91.
– reference: You SC, Kim KJ, Kim SU, et al. Hepatic fibrosis assessed using transient elastography is independently associated with coronary artery calcification. J Gastroenterol Hepatol 2015; 30: 1536-42.
– reference: Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15: 827-32.
– reference: Adibi P, Sadeghi M, Mahsa M, Rozati G, Mohseni M. Prediction of coronary atherosclerotic disease with liver transaminase level. Liver Int 2007; 27: 895-900.
– reference: Dogan S, Celikbilek M, Yilmaz YK, et al. Association between liver fibrosis and coronary heart disease risk in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2015; 27: 298-304.
– reference: Lonardo A, Ballestri S, Targher G, Loria P. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2015; 9: 629-50.
– reference: Chhabra R, O'Keefe JH, Patil H et al. Association of coronary artery calcification with hepatic steatosis in asymptomatic individuals. Mayo Clin Proc 2013; 88: 1259-1265.
– reference: Sumida Y, Yoneda M, Hyogo H, et al. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol 2012; 12: 2.
– reference: Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61: 1547-54.
– reference: Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-25.
– reference: Sattler S, Ghadially H, Hofer E. Evolution of the C-type lectin-like receptor genes of the DECTIN-1 cluster in the NK gene complex. Scientific World Journal 2012; 2012: 931386.
– reference: Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007; 132: 2169-80.
– reference: Tilg H, Moschen AR. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab 2008; 19: 371-9.
– reference: Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007; 191: 235-40.
– reference: Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
– reference: Sung KC, Wild SH, Kwag HJ, Byrne CD. Fatty liver, insulin resistance, and features of metabolic syndrome: relationships with coronary artery calcium in 10,153 people. Diabetes Care 2012; 35: 2359-64.
– reference: Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
– reference: Taye A, El-Sheikh AA. Lectin-like oxidized low-density lipoprotein receptor 1 pathways. Eur J Clin Invest 2013; 43: 740-5.
– reference: Takahashi Y, Kurosaki M, Tamaki N, et al. Non-alcoholic fatty liver disease fibrosis score and FIB-4 scoring system could identify patients at risk of systemic complications. Hepatology Research 2015; 45: 667-75.
– reference: Myers RP, Fong A, Shaheen AA. Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies. Liver Int 2008; 28: 705-12.
– reference: Treeprasertsuk S, Björnsson E, Enders F, Suwanwalaikorn S, Lindor KD. NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol 2013; 19: 1219-29.
– reference: Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52.
– reference: Rumberger JA, Brundage BH, Rader DJ, Kondos G. Electron beam computed tomographic coronary calcium scanning: a review and guidelines for use in asymptomatic persons. Mayo Clin Proc 1999; 74: 243-52.
– reference: Japan Atherosclerosis Society (JAS). Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012. Tokyo: JAS, 2012.
– reference: Kim D, Choi SY, Park EH, et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology 2012; 56: 605-13.
– reference: Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-50.
– reference: Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013; 57: 1357-65.
– reference: Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
– reference: Badman MK, Flier JS. The adipocyte as an active participant in energy balance and metabolism. Gastroenterology 2007; 132: 2103-15.
– reference: Fukui M, Tanaka M, Senmaru T, et al. LOX-1 is a novel marker for peripheral artery disease in patients with type 2 diabetes. Metabolism 2013; 62: 935-8.
– reference: Inoue N, Okamura T, Kokubo Y, et al. LOX index, a novel predictive biochemical marker for coronary heart disease and stroke. Clin Chem 2010; 56: 550-8.
– volume: 363
  start-page: 1341
  year: 2010
  end-page: 50
  article-title: Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease
  publication-title: N Engl J Med
– volume: 114
  start-page: 1761
  year: 2006
  end-page: 91
  article-title: Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology
  publication-title: Circulation
– volume: 17
  start-page: 188
  year: 2010
  end-page: 96
  article-title: Diagnostic and clinical benefit of combined coronary calcium and perfusion assessment in patients undergoing PET/CT myocardial perfusion stress imaging
  publication-title: J Nucl Cardiol
– volume: 19
  start-page: 371
  year: 2008
  end-page: 9
  article-title: Insulin resistance, inflammation, and non‐alcoholic fatty liver disease
  publication-title: Trends Endocrinol Metab
– volume: 308
  start-page: 788
  year: 2012
  end-page: 95
  article-title: Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate‐risk individuals
  publication-title: JAMA
– volume: 27
  start-page: 895
  year: 2007
  end-page: 900
  article-title: Prediction of coronary atherosclerotic disease with liver transaminase level
  publication-title: Liver Int
– volume: 132
  start-page: 2103
  year: 2007
  end-page: 15
  article-title: The adipocyte as an active participant in energy balance and metabolism
  publication-title: Gastroenterology
– volume: 40
  start-page: 1387
  year: 2004
  end-page: 95
  article-title: Prevalence of hepatic steatosis in an urban population in the : impact of ethnicity
  publication-title: Hepatology
– volume: 130
  start-page: 207
  year: 2006
  end-page: 10
  article-title: From fat to inflammation
  publication-title: Gastroenterology
– volume: 42
  start-page: 44
  year: 2005
  end-page: 52
  article-title: Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study
  publication-title: Hepatology
– volume: 116
  start-page: 1413
  year: 1999
  end-page: 9
  article-title: Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity
  publication-title: Gastroenterology
– volume: 7
  start-page: 234
  year: 2009
  end-page: 8
  article-title: Long‐term follow‐up of patients with nonalcoholic fatty liver
  publication-title: Clin Gastroenterol Hepatol
– article-title: Plasma soluble lectin‐like oxidized LDL receptor 1, a novel marker for atherosclerosis, is clinically associated with NAFLD histological severity
  publication-title: Hepatogastroenterology
– volume: 9
  start-page: 629
  year: 2015
  end-page: 50
  article-title: Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease
  publication-title: Expert Rev Gastroenterol Hepatol
– volume: 57
  start-page: 1441
  year: 2008
  end-page: 7
  article-title: Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease
  publication-title: Gut
– volume: 45
  start-page: 667
  year: 2015
  end-page: 75
  article-title: Non‐alcoholic fatty liver disease fibrosis score and FIB‐4 scoring system could identify patients at risk of systemic complications
  publication-title: Hepatology Research
– volume: 56
  start-page: 605
  year: 2012
  end-page: 13
  article-title: Nonalcoholic fatty liver disease is associated with coronary artery calcification
  publication-title: Hepatology
– volume: 88
  start-page: 1259
  year: 2013
  end-page: 1265
  article-title: Association of coronary artery calcification with hepatic steatosis in asymptomatic individuals
  publication-title: Mayo Clin Proc
– volume: 2012
  start-page: 931386
  year: 2012
  article-title: Evolution of the C‐type lectin‐like receptor genes of the DECTIN‐1 cluster in the NK gene complex
  publication-title: Scientific World Journal
– volume: 38
  start-page: 518
  year: 2003
  end-page: 26
  article-title: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C
  publication-title: Hepatology
– volume: 43
  start-page: 1317
  year: 2006
  end-page: 25
  article-title: Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection
  publication-title: Hepatology
– volume: 15
  start-page: 827
  year: 1990
  end-page: 32
  article-title: Quantification of coronary artery calcium using ultrafast computed tomography
  publication-title: J Am Coll Cardiol
– volume: 28
  start-page: 705
  year: 2008
  end-page: 12
  article-title: Utilization rates, complications and costs of percutaneous liver biopsy: a population‐based study including 4275 biopsies
  publication-title: Liver Int
– volume: 94
  start-page: 2467
  year: 1999
  end-page: 74
  article-title: Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions
  publication-title: Am J Gastroenterol
– year: 2012
– volume: 61
  start-page: 1231
  year: 2013
  end-page: 9
  article-title: Progression of coronary calcium and incident coronary heart disease events: MESA (Multi‐Ethnic Study of Atherosclerosis)
  publication-title: J Am Coll Cardiol
– volume: 40
  start-page: 775
  year: 1987
  end-page: 84
  article-title: Representativeness of the Framingham risk model for coronary heart disease mortality: a comparison with a national cohort study
  publication-title: J Chronic Dis
– volume: 25
  start-page: 419
  year: 2011
  end-page: 29
  article-title: Oxidized LDL, LOX‐1 and atherosclerosis
  publication-title: Cardiovasc Drugs Ther
– volume: 57
  start-page: 1357
  year: 2013
  end-page: 65
  article-title: Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the
  publication-title: Hepatology
– volume: 78
  start-page: 1501
  year: 2004
  end-page: 5
  article-title: Noninvasive evaluation of graft steatosis in living donor liver transplantation
  publication-title: Transplantation
– volume: 12
  start-page: 2
  year: 2012
  article-title: Validation of the FIB4 index in a nonalcoholic fatty liver disease population
  publication-title: BMC Gastroenterol
– volume: 19
  start-page: 1219
  year: 2013
  end-page: 29
  article-title: NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients
  publication-title: World J Gastroenterol
– volume: 35
  start-page: 2359
  year: 2012
  end-page: 64
  article-title: Fatty liver, insulin resistance, and features of metabolic syndrome: relationships with coronary artery calcium in 10,153 people
  publication-title: Diabetes Care
– volume: 30
  start-page: 2119
  year: 2007
  end-page: 21
  article-title: Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients
  publication-title: Diabetes Care
– volume: 191
  start-page: 235
  year: 2007
  end-page: 40
  article-title: Non‐alcoholic fatty liver disease and increased risk of cardiovascular disease
  publication-title: Atherosclerosis
– volume: 49
  start-page: 1860
  year: 2007
  end-page: 70
  article-title: Long‐term prognosis associated with coronary calcification: observations from a registry of 25,253 patients
  publication-title: J Am Coll Cardiol
– volume: 61
  start-page: 1547
  year: 2015
  end-page: 54
  article-title: Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up
  publication-title: Hepatology
– volume: 62
  start-page: 935
  year: 2013
  end-page: 8
  article-title: LOX‐1 is a novel marker for peripheral artery disease in patients with type 2 diabetes
  publication-title: Metabolism
– volume: 30
  start-page: 1536
  year: 2015
  end-page: 42
  article-title: Hepatic fibrosis assessed using transient elastography is independently associated with coronary artery calcification
  publication-title: J Gastroenterol Hepatol
– volume: 7
  start-page: 1104
  year: 2009
  end-page: 1112
  article-title: Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease
  publication-title: Clin Gastroenterol Hepatol
– volume: 43
  start-page: 740
  year: 2013
  end-page: 5
  article-title: Lectin‐like oxidized low‐density lipoprotein receptor 1 pathways
  publication-title: Eur J Clin Invest
– volume: 132
  start-page: 2169
  year: 2007
  end-page: 80
  article-title: Obesity, inflammation, and insulin resistance
  publication-title: Gastroenterology
– volume: 74
  start-page: 243
  year: 1999
  end-page: 52
  article-title: Electron beam computed tomographic coronary calcium scanning: a review and guidelines for use in asymptomatic persons
  publication-title: Mayo Clin Proc
– volume: 56
  start-page: 550
  year: 2010
  end-page: 8
  article-title: LOX index, a novel predictive biochemical marker for coronary heart disease and stroke
  publication-title: Clin Chem
– volume: 20
  start-page: 475
  year: 2014
  end-page: 85
  article-title: Limitations of liver biopsy and non‐invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
  publication-title: World J Gastroenterol
– volume: 27
  start-page: 298
  year: 2015
  end-page: 304
  article-title: Association between liver fibrosis and coronary heart disease risk in patients with nonalcoholic fatty liver disease
  publication-title: Eur J Gastroenterol Hepatol
– volume: 28
  start-page: 412
  year: 1985
  end-page: 9
  article-title: Home‐ ostasis model assessment: insulin resistance and ‐cell function from fasting glucose and insulin concentrations in man
  publication-title: Diabetologia
– volume: 29
  start-page: 939
  year: 2008
  end-page: 60
  article-title: Causes and metabolic consequences of fatty liver
  publication-title: Endocr Rev
– ident: e_1_2_6_4_1
  doi: 10.1016/S0016-5085(99)70506-8
– ident: e_1_2_6_17_1
  doi: 10.1002/hep.26156
– ident: e_1_2_6_15_1
  doi: 10.1111/j.1478-3231.2008.01691.x
– ident: e_1_2_6_34_1
  doi: 10.1586/17474124.2015.965143
– ident: e_1_2_6_26_1
  doi: 10.1136/gut.2007.146019
– ident: e_1_2_6_42_1
  doi: 10.1053/j.gastro.2005.11.017
– ident: e_1_2_6_11_1
  doi: 10.1161/CIRCULATIONAHA.106.178458
– ident: e_1_2_6_13_1
  doi: 10.1001/jama.2012.9624
– ident: e_1_2_6_31_1
  doi: 10.1002/hep.25593
– ident: e_1_2_6_36_1
  doi: 10.1097/MEG.0000000000000286
– ident: e_1_2_6_16_1
  doi: 10.3748/wjg.v19.i8.1219
– ident: e_1_2_6_23_1
  doi: 10.1002/hep.21178
– ident: e_1_2_6_25_1
  doi: 10.1053/jhep.2003.50346
– ident: e_1_2_6_47_1
  doi: 10.1100/2012/931386
– ident: e_1_2_6_44_1
  doi: 10.1210/er.2008-0009
– ident: e_1_2_6_48_1
  doi: 10.1111/eci.12092
– ident: e_1_2_6_18_1
  doi: 10.1002/hep.27368
– volume-title: Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012
  year: 2012
  ident: e_1_2_6_21_1
– ident: e_1_2_6_32_1
  doi: 10.2337/dc12-0515
– ident: e_1_2_6_43_1
  doi: 10.1053/j.gastro.2007.03.059
– ident: e_1_2_6_2_1
  doi: 10.1002/hep.20466
– ident: e_1_2_6_45_1
  doi: 10.1016/j.tem.2008.08.005
– ident: e_1_2_6_39_1
  doi: 10.1111/hepr.12405
– ident: e_1_2_6_30_1
  doi: 10.1007/s12350-009-9159-9
– ident: e_1_2_6_22_1
  doi: 10.1007/BF00280883
– ident: e_1_2_6_20_1
  doi: 10.1111/j.1572-0241.1999.01377.x
– ident: e_1_2_6_38_1
  doi: 10.1002/hep.26156
– ident: e_1_2_6_37_1
  doi: 10.1111/jgh.12992
– ident: e_1_2_6_40_1
  doi: 10.1186/1471-230X-12-2
– ident: e_1_2_6_41_1
  doi: 10.1053/j.gastro.2007.03.058
– ident: e_1_2_6_35_1
  doi: 10.1016/0021-9681(87)90129-9
– ident: e_1_2_6_12_1
  doi: 10.1016/j.jacc.2006.10.079
– ident: e_1_2_6_3_1
  doi: 10.1002/hep.20734
– ident: e_1_2_6_10_1
  doi: 10.1111/j.1478-3231.2007.01545.x
– ident: e_1_2_6_14_1
  doi: 10.1016/j.jacc.2012.12.035
– ident: e_1_2_6_33_1
  doi: 10.1016/j.mayocp.2013.06.025
– ident: e_1_2_6_46_1
  article-title: Plasma soluble lectin‐like oxidized LDL receptor 1, a novel marker for atherosclerosis, is clinically associated with NAFLD histological severity
  publication-title: Hepatogastroenterology
– ident: e_1_2_6_28_1
  doi: 10.1097/01.TP.0000140499.23683.0D
– ident: e_1_2_6_27_1
  doi: 10.1016/0735-1097(90)90282-T
– ident: e_1_2_6_50_1
  doi: 10.1016/j.metabol.2013.01.018
– ident: e_1_2_6_6_1
  doi: 10.1056/NEJMra0912063
– ident: e_1_2_6_9_1
  doi: 10.1016/j.atherosclerosis.2006.08.021
– ident: e_1_2_6_7_1
  doi: 10.1007/s10557-011-6341-5
– ident: e_1_2_6_19_1
  doi: 10.1016/j.cgh.2009.05.033
– ident: e_1_2_6_8_1
  doi: 10.2337/dc07-0349
– ident: e_1_2_6_29_1
  doi: 10.4065/74.3.243
– ident: e_1_2_6_49_1
  doi: 10.1373/clinchem.2009.140707
– ident: e_1_2_6_5_1
  doi: 10.1016/j.cgh.2008.11.005
– ident: e_1_2_6_24_1
  doi: 10.3748/wjg.v20.i2.475
SSID ssj0017024
Score 2.2456384
Snippet Aims Cardiovascular events are the leading cause of death among patients with non‐alcoholic fatty liver disease (NAFLD), but their relationship remains...
Cardiovascular events are the leading cause of death among patients with non-alcoholic fatty liver disease (NAFLD), but their relationship remains unclear....
AIMSCardiovascular events are the leading cause of death among patients with non-alcoholic fatty liver disease (NAFLD), but their relationship remains unclear....
SourceID proquest
pubmed
crossref
wiley
istex
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1107
SubjectTerms coronary artery calcification
coronary artery disease
FIB-4 index
liver fibrosis
non-alcoholic fatty liver disease
Title Association of coronary artery calcification with liver fibrosis in Japanese patients with non-alcoholic fatty liver disease
URI https://api.istex.fr/ark:/67375/WNG-W8MS9WPX-S/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fhepr.12665
https://www.ncbi.nlm.nih.gov/pubmed/26853695
https://www.proquest.com/docview/1826652960
Volume 46
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVEBS
  databaseName: EBSCOhost Academic Search Ultimate
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 1872-034X
  dateEnd: 20241102
  omitProxy: true
  ssIdentifier: ssj0017024
  issn: 1386-6346
  databaseCode: ABDBF
  dateStart: 20070101
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVWIB
  databaseName: Wiley Online Library - Core collection (SURFmarket)
  issn: 1386-6346
  databaseCode: DR2
  dateStart: 20070101
  customDbUrl:
  isFulltext: true
  eissn: 1872-034X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017024
  providerName: Wiley-Blackwell
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fSxwxEA9iQfpSW23r9R8plkILe7iX3ewGfJGiPYQT0crdSwlJLsFDuZPbPah9KP0I_Yx-EmeS7FZFChb2YR9mL7nJzOY3mdnfEPKhtJkeu1wlXDkIUAxnSTkej5NSaSOEEU54tv3BAe-fZPujfLREtptvYQI_RHvghp7h39fo4EpXN5z81F7MuynsL_iFecq4j6eOWu6otNiKHW1LnnCW8chNimU8fx-9tRs9QsX-uA9q3kaufuvZWyXfm0mHipOz7qLWXfPzDp_j__6rp-RJxKR0JxjRM7Jkp2tkZRCz7uvk1401pDNHDbIewBDU14NeUlhmX9kXBPBkl55juQd1MJVZNanoZEr3YVfGbpc0MrlWQXA6m179_qNCo96JoU7V9WV8PCaPnpOTvd1vX_pJ7NuQmAwAUpJpwSy8BxSzNsMTS7gMK5TOVeEAHmhTCm2R-s0yzOwx42B9dCEAWvQwL_mCLMPodoNQ5wTE7wrMHUTSFCwnNwA4WG50zwIy6ZBPzfpJE0nNsbfGuWyCG1So9ArtkM1W9iJQedwr9dGbQSui5mdY_FbkcnjwVQ7LwbEYHo7kcYe8b-xEgktingXUOFtUEkM2jvnsrQ55GQyo_bUeBwVwAcN89mbwj5nI_u7hkb979RDh1-QxgDoeCg7fkOV6vrBvATjV-p13kGs8dxaV
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED_BJgEvfH8UBhiBkJiUam0SJ36c0EYZazXtQ-2bZbu2qDa1U5NKjAfEn8DfuL9kd7YbNjQhgZSHPFzi5HwX_853-R3Au9JmeuxylXDlMEAxPE3K8XiclEobIYxwwrPt9we8d5TtjPJRrM2hf2ECP0Sz4Uae4b_X5OC0IX3Jy7_a03m7gwtMfhNWM46BCmGi_YY9qlNsxJ62JU94mvHITkqFPL-vvbIerZJqv10HNq9iV7_4bN8LHVYrz1lINSfH7UWt2-b7H4yO__1e9-FuhKVsM9jRA7hhpw_hVj8m3h_Bj0vTyGaOGSI-wDGYLwk9YzjTvrgvCNDmLjuhig_m8Flm1aRikynbwYWZGl6ySOZaBcHpbHr-85cKvXonhjlV12fx8pg_egxH21uHH3tJbN2QmAwxUpJpkVr8FKjU2ow2LfEwaaF0rgqHCEGbUmhL7G82peReahxOkC4EoosupSafwAqObp8Bc05gCK_Q4lGk00HjyQ1ijjQ3umsRnLTgw3ICpYm85tRe40Qu4xtSqPQKbcHbRvY0sHlcK_Xe20EjoubHVP9W5HI4-CSHZf9ADPdG8qAFb5aGItErKdWCapwtKklRG6eU9kYLngYLau7W5agALnCYdW8Hf3kS2dva2_dnz_9F-DXc7h32d-Xu58GXF3AHMR4P9YdrsFLPF_Yl4qhav_LecgGbZhq2
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELZgkyZe2Pi1FRgYgZBASrU2iRM_TttKGbSqNqb2zbIdW6s2tVWTShsPiD-Bv3F_ye5sN2xoQgKpD3241Mn5Lv7s-_odIe9yk6jCpjJi0sIGRbM4youiiHKpNOeaW-7U9nt91j1JDkfpKHBz8L8wXh-iPnDDzHDva0xwMyvsjSw_NbN5swULTHqfrCYpz5HRt39Uq0e1sp3Q0zZnEYsTFtRJkcjz-9pb69EquvbiLrB5G7u6xaez7juslk6zEDknZ81FpZr6-x-Kjv_9XBvkYYCldNfH0SNyz0wek7VeKLw_IT9uTCOdWqpR-ADGoI4Seklhph25zxvg4S49R8YHtXAv03Jc0vGEHsLCjA0vaRBzLb3hZDq5-vlL-l69Y02trKrLcHmoHz0lJ52Db3vdKLRuiHQCGClKFI8NvApkbEyCh5bw0XEmVSozCwhB6Zwrg-pvJsbiXqwtTJDKOKCLNpYmn5EVGN1sEWothy28hIgHk1YLgifVgDniVKu2AXDSIB-WEyh00DXH9hrnYrm_QYcK59AGeVvbzryax51W710c1CZyfob8tywVw_4nMcx7x3w4GInjBnmzDBQBWYmlFnDjdFEK3LUxLGnvNMimj6D619oMHMA4DPPRxcFf7kR0DwZH7tvzfzF-TdYG-x3x9XP_ywvyACAe8_TDl2Slmi_MNsCoSr1yyXININkaOg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Association+of+coronary+artery+calcification+with+liver+fibrosis+in+Japanese+patients+with+non-alcoholic+fatty+liver+disease&rft.jtitle=Hepatology+research&rft.au=Ishiba%2C+Hiroshi&rft.au=Sumida%2C+Yoshio&rft.au=Kataoka%2C+Seita&rft.au=Kuroda%2C+Masaaki&rft.date=2016-10-01&rft.issn=1386-6346&rft.volume=46&rft.issue=11&rft.spage=1107&rft.epage=1117&rft_id=info:doi/10.1111%2Fhepr.12665&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1386-6346&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1386-6346&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1386-6346&client=summon